Showing results (2281-2290 of 3,034) with videos related to

Sort By:
Pageof 304
European Journal of Haematology|March 28, 2008
Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myelomaSebastian Belle, Fang Han, Maud Condomines, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 28, 2014
Selective treatment and monitoring of disseminated cancer micrometastases in vivo using dual-function, activatable immunoconjugatesBryan Q Spring, Adnan O Abu-Yousif, Akilan Palanisami, et al.
Archives of Surgery (Chicago, Ill. : 1960)|June 12, 2003
Upstaging of atypical ductal hyperplasia after vacuum-assisted 11-gauge stereotactic core needle biopsyDavid J Winchester, Joel R Bernstein, Jan M Jeske, et al.
Anticancer Research|November 7, 2018
Hairy Cell Leukemia: Retrospective Analysis of Demographic Data and Outcome of 203 Patients from 12 Medical Centers in IsraelMichal Inbar, Yair Herishanu, Neta Goldschmidt, et al.
Cancers|March 6, 2021
Analyzing Longitudinal wb-MRI Data and Clinical Course in a Cohort of Former Smoldering Multiple Myeloma Patients: Connections between MRI Findings and Clinical Progression PatternsMarkus Wennmann, Thomas Hielscher, Laurent Kintzelé, et al.
Blood|March 7, 2007
Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myelomaKarène Mahtouk, Dirk Hose, Pierre Raynaud, et al.
Plos Pathogens|July 23, 2013
Cytotoxic T cells mediate pathology and metastasis in cutaneous leishmaniasisFernanda O Novais, Lucas P Carvalho, Joel W Graff, et al.
Haematologica|July 21, 2007
Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized studyJean-Henri Bourhis, Yasmina Bouko, Serge Koscielny, et al.
Blood|September 18, 2015
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and olderAndres Forero-Torres, Beata Holkova, Jerome Goldschmidt, et al.
The International Journal of Eating Disorders|August 19, 2015
A naturalistic examination of the temporal patterns of affect and eating disorder behaviors in anorexia nervosaJason M Lavender, Linsey M Utzinger, Ross D Crosby, et al.
Pageof 304